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Equitable access to essential medicines and diagnostic tools is crucial for improving global public health and promoting sustainable health development efforts. Many individuals suffering from health chal-lenges around the world still do not have access to existing life-saving interventions due to lack of avail-
ability and high costs. The devastating effects of these inequities and discussions about their solutions have 
been at the forefront during the COVID-19 pandemic.
Health experts have long been working to identify effective meth-
ods of increasing access to medicines (AtM) that also incentivize 
research and development (R&D) by drug manufacturers. In the 
last two decades, the number of industry-led AtM programs im-
plemented has substantially increased [1], with the pharmaceu-
tical industry more openly recognizing a human rights obliga-
tion to improve access to medicines [2]. As argued by the Lancet 
Commission on Essential Medicines Policies, despite the existence of 
many industry-led AtM programs and the independent AtM In-
dex that ranks 20 of the world's largest R&D-based pharmaceu-
tical companies, rigorous evaluation remains a key challenge [3]. 
In response, the 2021 AtM Index report adapted various indicators to expand how it measures companies' 
evaluation efforts and used tighter analytical framework centered on governance of access, research and de-
velopment, and product delivery [4]. Figure 1 illustrates a representative set of indicators that were changed 
between the 2018 and 2021 reports, with a full listing provided in Figure S1 in the Online Supplementary 
Document. This most recent report was released in January 2021 to assess the actions taken by pharma-
ceutical companies to expand access to medicine for people living in low- and middle-income countries. It 
also captures the industry’s response to the ongoing pandemic, identifying 63 new R&D projects in compa-
nies’ pipelines targeting COVID-19. The report also highlighted that the COVID-19 pandemic has caused 
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The need to promote greater rigor 
and transparency in AtM programs is 
essential to understanding how well 
these programs are actually doing to 
achieve desired goals to increase ac-
cess and improve health outcomes.
further problems with funding competi-
tion for other AtM initiatives, such as to 
combat malaria, TB, and HIV/AIDS [5]. 
The Index reported that all 20 compa-
nies assessed now take steps to measure 
outcomes of AtM initiatives, up from 13 
companies in 2018. Outcomes are made 
public for more than half of initiatives as-
sessed (43 of 82). Also released in January 
2021 was the Second World Health Or-
ganization (WHO) Model List of Essential 
In Vitro Diagnostics (EDL), which pro-
vides a comprehensive list of diagnostic 
tests necessary for universal health cover-
age that can be tailored to local circum-
stances [6]. The latest edition was revised 
to include COVID-19 nucleic acid ampli-
fication and antigen detecting tests as a 
necessary In Vitro Diagnostics. The WHO 
has previously worked with many coun-
tries to make noncommunicable disease 
diagnostic testing available in low- and 
middle-income countries, which has led 
to the development of resources like the 
National Free Diagnostic Service Initia-
tive, which provides services in India [7]. Similar resources for COVID-19 are essential to stopping the 
spread of COVID-19 and improving global health.
In addition to the AtM Index, another major effort to improve reporting on AtM programs is Access Acceler-
ated and its Access Observatory, which attempts not only to collect data, which is made publicly available, 
but also to devise a standardized measurement framework [8]. Their evaluation of pilot programs in the Phil-
ippines and Ghana suggests that differential pricing aided with health care strengthening can increase access 
to medicines [9].
A variety of factors continue to serve as barriers to conducting widespread, robust program evaluations, in-
cluding the lack of specific data about drugs, quality medicine pricing data, and household usage of drugs. In 
addition, companies often lack incentives to collect and report high-quality impact data.
Despite these challenges, there are a small number of pharmaceutical com-
panies that have conducted robust evaluations in the past. While none of 
the 120 AtM initiatives evaluated by Rockers et al. in 2017 met the high-
quality threshold under the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) system, three studies were classi-
fied as moderate quality: (1) Merck MSD’s Mectizan Donation Program, 
(2) the Pfizer International Trachoma Initiative, and (3) Novartis’s Access 
program in Kenya. The Novartis Access study was the first randomized 
assessment of the impact of a pharmaceutical industry-led AtM program, 
and initial results indicate that even offering medicines at US$1 per treat-
ment per month did not significantly improve overall access nor reduce prices of the medicine after one 
year [10]. The study will be extended over a two-year period to test the factors which might have contrib-
uted to these results, which underscores the need for rigorous evaluations to understand and overcome 
barriers to access.
Program design varies widely between AtM initiatives, with the 120 AtM initiatives assessed in 2017 employ-
ing the following strategies: medicine donation (48%), price reduction (44%), licensing agreements (22%), 
and supply chain strengthening (11%). It has been found that bulk donations are more likely to be unsustain-
able and even cause harm in the long run by reducing competition [11]. General price reduction as a strategy 
alone may run the risk of not addressing other accessibility issues in a specific region. Increasing the quality of 
Figure 1. A small representative set of indicators are presented that were changed between 
the 2018 and 2021 Access to Medicines Index reports. A comprehensive listing of indi-
cators and the changes between those used in 2018 and 2021 are provided in Figure S1 
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evaluations is necessary to determine the success of cer-
tain AtM strategies in a variety of contexts. More inno-
vative, long-term approaches to improving AtM should 
also be explored, including differential pricing, voluntary 
licensing, and patent pooling [12]. Some of the metrics 
revised for the 2021 AtM Index aim to better measure 
the scale and long-term sustainability of companies’ AtM 
strategies.
The urgent need to overcome COVID-19 has prioritized 
AtM among global leaders. In May 2020, the World 
Health Assembly adopted a resolution that calls for in-
creased collaboration through “existing mechanisms for 
voluntary pooling and licensing of patents” to mitigate 
the COVID-19 pandemic and for “equitable access to and 
fair distribution of all essential health technologies and 
products to combat the novel coronavirus.” The resolution was co-sponsored by more than 130 countries and 
adopted by consensus [13]. Coupling expanded access with more rigorous and transparent evaluations will 
help ensure that best practices lead to desired outcomes and minimize unintended consequences. Fortunately, 
many actors across industry, academia, and public health recognize the need to prioritize equity, accountabil-
ity, independence, and sound evidence. In doing so, companies can move toward strengthening their reputa-
tions while increasing meaningful impact that has the potential to save lives.
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